CLDX:NSD-Celldex Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 27.08

Change

-0.43 (-1.56)%

Market Cap

USD 1.09B

Volume

0.42M

Average Target Price

USD 35.50 (+31.09%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+6.43 (+4.33%)

USD58.72B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.43 (-0.20%)

USD55.37B 20.70 14.64
REGN Regeneron Pharmaceuticals, Inc

-2.62 (-0.58%)

USD48.55B 14.85 12.06
ALXN Alexion Pharmaceuticals, Inc

-0.90 (-0.59%)

USD33.78B 56.49 34.28
BGNE BeiGene, Ltd

-9.73 (-2.95%)

USD29.41B N/A N/A
RPRX Royalty Pharma plc

-0.45 (-0.96%)

USD28.55B 22.60 14.73
BNTX BioNTech SE

-3.30 (-2.94%)

USD27.49B -99,999.99 N/A
SGEN Seagen Inc

+1.02 (+0.68%)

USD27.19B 44.54 41.48
GMAB Genmab A/S

+0.19 (+0.56%)

USD23.40B 26.59 3.51
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CLDX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 54.57% 85% B 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.57% 85% B 89% B+
Trailing 12 Months  
Capital Gain 929.66% 99% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 929.66% 99% A+ 98% A+
Trailing 5 Years  
Capital Gain -76.31% 21% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -76.31% 21% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain 55.11% 80% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.11% 80% B- 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 250.75% 8% F 5% F
Risk Adjusted Return 21.98% 53% F 48% F
Market Capitalization 1.09B 72% C- 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.09 67% D+ 45% F
Price / Cash Flow Ratio -23.45 76% C 82% B-
EV/EBITDA 0.01 98% A+ 100% A+
Management Effectiveness  
Return on Equity -29.17% 80% B- 31% F
Return on Invested Capital -49.44% 59% F 19% F
Return on Assets -16.76% 74% C 22% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.65 31% F 19% F
Short Percent 8.70% 34% F 23% F
Beta 2.71 6% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector